Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 14/20 | 0.44 |
| ▸ | RXRB | P28702 | 10/20 | 0.44 |
| ▸ | RARB | P10826 | 9/20 | 0.44 |
| ▸ | RARG | P13631 | 8/20 | 0.44 |
| ▸ | RXRG | P48443 | 6/20 | 0.44 |
| ▸ | RARA | P10276 | 6/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.41 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24055015 | 0.90 | HTR2A (0.42) | HTR2AHTR2CRXRARXRBRARB | |
| SCHEMBL24794223 | 0.84 | RARA (0.54) | RXRARARBRARGRARA | |
| SCHEMBL24794216 | 0.84 | RARA (0.54) | RXRARARBRARGRARA | |
| SCHEMBL27339304 | 0.79 | RARB (0.46) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL24795394 | 0.79 | PGR (0.57) | RXRARARBRARGRARA | |
| SCHEMBL26001634 | 0.79 | RXRA (0.35) | HTR2AHTR2CRXRARXRBRARB | |
| SCHEMBL192606 | 0.78 | HTR2A (0.61) | HTR2AHTR2C | |
| SCHEMBL24809810 | 0.78 | RARG (0.45) | RXRARARBRARGRARA | |
| SCHEMBL24794235 | 0.78 | PGR (0.60) | RARBRARGRARA | |
| SCHEMBL24794224 | 0.78 | RARB (0.60) | RXRARARBRARGRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024096578-A1 | COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT USING SAME, AND ELECTRONIC DEVICE HAVING SAME | 덕산네오룩스 주식회사 | 2024-05-10 | — | — | WO | disclosed |
| WO-2024096578-A1 | COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT USING SAME, AND ELECTRONIC DEVICE HAVING SAME | 덕산네오룩스 주식회사 | 2024-05-10 | — | — | WO | disclosed |
| US-7655699-B1 | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors | EISAI INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-20060106072-A1 | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors | EISAI INC. | 2006-05-18 | — | — | US | disclosed |
| US-6610883-B1 | Such as 3-methyl-5-(2-(2-(2,6,6-trimethylcyclohexen-1-yl)-ethenyl)phenyl)-2,4 -pentadienoic acid | LIGAND PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| US-6320074-B1 | IN VIVO MODULATION OF LIPID METABOLISM, SKIN-RELATED PROCESSES, AUTOIMMUNE DISEASES, FATTY ACID METABOLISM, MALIGNANT CELL DEVELOPMENT, PREMALIGNANT LESIONS, OR PROGRAMMED CELL DEATH | LIGAND PHARMACEUTICALS INCORPORATED | 2001-11-20 | — | — | US | disclosed |
| EP-0637297-B1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARM INC (US) | 2000-08-23 | — | — | EP | disclosed |
| US-6043279-A | COMPOUNDS USED FOR IN VIVO MODULATION OF LIPID METABOLISM, SKIN-RELATED PROCESSES, MALIGNANT CELL DEVELOPMENT, PREMALIGNANT LESIONS, PROGRAMMED CELL DEATH | LIGAND PHARMACEUTICALS, INCORPORATED (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0983991-A2 | Compounds having selectivity for retinoid x receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2000-03-08 | — | — | EP | disclosed |
| EP-0983992-A2 | Compounds having selectivity for retinoid x receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2000-03-08 | — | — | EP | disclosed |
| EP-0678087-B1 | COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS | LIGAND PHARM INC (US) | 1999-03-17 | — | — | EP | disclosed |
| US-5780676-A | BICYCLIC BENZYL, PYRIDINYL, THIOPHENE, FURANYL, PYRROLE, AND POLYENOIC ACID DERIVATIVES | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0678087-A1 | COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0678086-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0637297-A4 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS. | LIGAND PHARM INC (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995004036-A1 | COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1995-02-09 | — | — | WO | disclosed |
| EP-0637297-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-02-08 | — | — | EP | disclosed |
| WO-1994015901-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1994015902-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1993021146-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106072-A1 | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors | RXRB, RXRA, RXRG | HTR2A 2957/4885HTR2C 2656/4885RXRA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.